EcoDrugPlus

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSCGOG00000014567
Gene Symbol: LOC115004524
3 Cross references
189 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSCGOG00000002197
Gene Symbol: LOC115015964
3 Cross references
195 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSCGOG00000012408
Gene Symbol: LOC115022371
3 Cross references
200 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSCGOG00000013924
Gene Symbol: LOC115016117
3 Cross references
191 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSCGOG00000012302
Gene Symbol: LOC115021863
3 Cross references
187 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone)

Ensembl ID : ENSCGOG00000022193
Gene Symbol: DHODH
3 Cross references
173 Possible Orthologues:

Dihydropyridine-Sensitive L-Type Skeletal Muscle Calcium Channel Subunit Alpha-1-Like

Ensembl ID : ENSCGOG00000002855
Gene Symbol: LOC115007829
3 Cross references
196 Possible Orthologues:

Dihydropyridine-Sensitive L-Type Skeletal Muscle Calcium Channel Subunit Alpha-1-Like

Ensembl ID : ENSCGOG00000009136
Gene Symbol: LOC115010609
3 Cross references
196 Possible Orthologues:

Dihydropyrimidine Dehydrogenase [Nadp(+)]-Like

Ensembl ID : ENSCGOG00000019732
Gene Symbol: LOC115022154
3 Cross references
217 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSCGOG00000005853
Gene Symbol: DDR2
3 Cross references
205 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSCGOG00000019729
Gene Symbol: DDR2
3 Cross references
189 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSCGOG00000013708
Gene Symbol: DRD1
3 Cross references
189 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).